DAB2IP also acts as a negative modulator of HSP90AA1 in colorectal cancer; through an unknown mechanism, DAB2IP inhibits HSP90AA1-mediated upregulation of SRP9, fostering activation of the pro-apoptotic JNK/ASK1 pathway and counteracting metastasis [17]. Here, DAB2IP is linked to colorectal cancer.